Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...
2024-02-02 22:22
2840
First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke
TAIPEI, , July 31, 2017 /PRNewswire/ -- Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce the enrollment of the first subject for the Phase 1 clinical trial of its new drug candidate, LT3001, for acute ischemic stroke. The first human subject was dosed wi...
2017-08-01 09:46
4275
